Javascript must be enabled to continue!
XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
View through CrossRef
Pancreatic adenocarcinoma (PAC) is one of the most aggressive human cancers and new systemic therapies are urgently needed. Exportin-1 (XPO1), which is a member of the importin-β superfamily of karyopherins, is the major exporter of many tumor suppressor proteins that are involved in the progression of PAC. Promising pre-clinical data using XPO1 inhibitors have been reported in PAC, but very few data are available regarding XPO1 expression in clinical samples. Retrospectively, we analyzed XPO1 mRNA expression in 741 pancreatic samples, including 95 normal, 73 metastatic and 573 primary cancers samples, and searched for correlations with clinicopathological and molecular data, including overall survival. XPO1 expression was heterogeneous across the samples, higher in metastatic samples than in the primary tumors, and higher in primaries than in the normal samples. “XPO1-high” tumors were associated with positive pathological lymph node status and aggressive molecular subtypes. They were also associated with shorter overall survival in both uni- and multivariate analyses. Supervised analysis between the “XPO1-high” and “XPO1-low” tumors identified a robust 268-gene signature, whereby ontology analysis suggested increased XPO1 activity in the “XPO1-high” tumors. XPO1 expression refines the prognostication in PAC and higher expression exists in secondary versus primary tumors, which supports the development of XPO1 inhibitors in this so-lethal disease.
Title: XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
Description:
Pancreatic adenocarcinoma (PAC) is one of the most aggressive human cancers and new systemic therapies are urgently needed.
Exportin-1 (XPO1), which is a member of the importin-β superfamily of karyopherins, is the major exporter of many tumor suppressor proteins that are involved in the progression of PAC.
Promising pre-clinical data using XPO1 inhibitors have been reported in PAC, but very few data are available regarding XPO1 expression in clinical samples.
Retrospectively, we analyzed XPO1 mRNA expression in 741 pancreatic samples, including 95 normal, 73 metastatic and 573 primary cancers samples, and searched for correlations with clinicopathological and molecular data, including overall survival.
XPO1 expression was heterogeneous across the samples, higher in metastatic samples than in the primary tumors, and higher in primaries than in the normal samples.
“XPO1-high” tumors were associated with positive pathological lymph node status and aggressive molecular subtypes.
They were also associated with shorter overall survival in both uni- and multivariate analyses.
Supervised analysis between the “XPO1-high” and “XPO1-low” tumors identified a robust 268-gene signature, whereby ontology analysis suggested increased XPO1 activity in the “XPO1-high” tumors.
XPO1 expression refines the prognostication in PAC and higher expression exists in secondary versus primary tumors, which supports the development of XPO1 inhibitors in this so-lethal disease.
Related Results
Étude des anomalies de XPO1 dans les lymphomes B
Étude des anomalies de XPO1 dans les lymphomes B
L'exportine-1 (ou XPO1) joue un rôle clé dans le transport de nombreux ARN et près de 200 protéines cargos. La mutation « hot-spot » XPO1-E571K est présente chez près de 25% des pa...
Pharmacologic Inhibition of XPO1 By Selinexor Improves Late-Stage Erythropoiesis in Severely Affected β 0-Thalassemia/Hemoglobin E
Pharmacologic Inhibition of XPO1 By Selinexor Improves Late-Stage Erythropoiesis in Severely Affected β 0-Thalassemia/Hemoglobin E
Ineffective erythropoiesis due to accumulation of excess α-globin chains profounds unwarranted consequences in β-thalassemia. In severe β-thalassemia, the excess α-globin chains tr...
Abstract B055: XPO1-dependent nuclear export as a therapeutic target for ALK-positive non-small cell lung cancers
Abstract B055: XPO1-dependent nuclear export as a therapeutic target for ALK-positive non-small cell lung cancers
Abstract
EML4-ALK fusion has emerged as a significant oncogenic driver in Non-Small Cell Lung Cancer (NSCLC), promoting ...
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract
Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancers today and is expected to be the second cause of cancer death in the coming decade. M...
High KLK7 Expression Predicts Unfavorable Outcomes in Patients with Resectable Pancreatic Ductal Adenocarcinoma
High KLK7 Expression Predicts Unfavorable Outcomes in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Abstract
Background Studies have shown that kallikrein-related peptidase 7 (KLK7) is abnormally expressed in a various of tumours and plays a crucial role in tumour progres...
Abstract 5716: XPO1 inhibition synergizes with PARP inhibitor in metastatic castration resistant prostate cancer via the regulation of DNA damage response
Abstract 5716: XPO1 inhibition synergizes with PARP inhibitor in metastatic castration resistant prostate cancer via the regulation of DNA damage response
Abstract
Background:
Dysregulated nuclear protein transport, commonly observed in cancer, results in the mislocalization-mediate...
Potential regulatory mechanisms of hsa_circ_0131457/miR-636/SFRP2 inhibition of tumor progression in pancreatic ductus adenocarcinoma
Potential regulatory mechanisms of hsa_circ_0131457/miR-636/SFRP2 inhibition of tumor progression in pancreatic ductus adenocarcinoma
Abstract
Background: Circular RNAs (circRNAs), a novel class of non-coding RNAs, have been found to act as miRNA sponges that competitively inhibit the binding of miRNA to ...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...

